Bumetanide

From Wikipedia, the free encyclopedia

Bumetanide
Systematic (IUPAC) name
3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
Identifiers
CAS number 28395-03-1
ATC code C03CA02
PubChem 2471
DrugBank APRD00294
Chemical data
Formula C17H20N2O5S 
Mol. mass 364.417 g/mol
Pharmacokinetic data
Bioavailability almost complete
Protein binding 97%
Metabolism hepatic
Half life 60-90 minutes
Excretion renal
Therapeutic considerations
Pregnancy cat.

B3(AU) C(US)

Legal status

Prescription Only (S4)(AU) POM(UK) -only(US)

Routes oral

Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure. It is often used in patients in whom high doses of furosemide are ineffective. It is marketed by Hoffmann-La Roche with the brand name Bumex. There is however no reason not to use bumetanide as a first choice drug. The main difference between the two substances is in bioavailability. Furosemide is incompletely absorbed in the intestine (40%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.

Bumetanide is 40 times more potent than furosemide (for patients with normal renal function).

[edit] External links


In other languages